GLP-1 drugs show promise beyond weight loss: heart, kidney, liver, Alzheimer's

The article reviews emerging evidence that GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro) may have benefits beyond weight loss, including cardiovascular, renal, hepatic, and neuroprotective effects. The claims are based on clinical trials and mechanistic studies, but long-term efficacy and safety remain uncertain. This matters because expanding indications could significantly impact healthcare costs and pharmaceutical markets.